Tuberous Sclerosis: Cutaneous Manifestations

Tuberous sclerosis complex (TSC) is a multisystem autosomal dominant genetic disorder characterized by benign hamartomatous tumors in multiple organs including skin, brain, kidney, lung, heart, and eye. Prevalence is approximately 1:6000-10000 live births, making it one of the most common genetic disorders. Genetics: caused by loss-of-function mutations in either TSC1 gene (chromosome 9q34, encodes hamartin protein, 1/3 of cases) or TSC2 gene (chromosome 16p13.3, encodes tuberin protein, 2/3 of cases, often more severe phenotype). The hamartin-tuberin complex normally inhibits Rheb (Ras homolog enriched in brain) GTPase, which activates mTORC1 (mTOR complex 1). Loss of TSC1 or TSC2 function leads to constitutive activation of mTORC1, driving cell growth, proliferation, and decreased autophagy, resulting in hamartomatous tumor formation. Approximately 2/3 of cases are sporadic (de novo mutations), 1/3 inherited from affected parent. Variable expressivity and incomplete penetrance create significant phenotypic variability even within the same family.

Cutaneous manifestations are present in over 90% of TSC patients and serve as the most accessible diagnostic clues, often providing the first sign of the disease. Major cutaneous criteria (per 2012 revised diagnostic criteria, Northrup et al.): (1) Hypomelanotic macules: 3 or more, at least 5 mm diameter, characteristic ash-leaf shape (oval with one pointed end), often present at birth or early infancy, best appreciated with Wood lamp examination especially in fair-skinned individuals. Histology shows reduced melanin and number of melanocytes. Most common cutaneous finding (90% of patients). (2) Angiofibromas: 3 or more, characteristic butterfly distribution on cheeks, nose, nasolabial folds, sometimes forehead and chin. Develop typically between ages 2-5, increase in number through puberty. Pink to red dome-shaped papules 1-10 mm. Histology shows hamartomatous proliferation of dermal fibroblasts and dilated blood vessels. Associated with poor self-image and social isolation. (3) Shagreen patches: irregular plaques of thickened, leathery skin with orange peel texture, typically located on lumbosacral region, less commonly on trunk or thighs. Develop in childhood or adolescence. Histology shows increased collagen and disorganized dermal architecture. (4) Ungual fibromas (Koenen tumors): smooth pink or flesh-colored papules emerging from nail folds (periungual) or beneath nail (subungual), more common in toes than fingers, develop in adolescence and adulthood, may cause longitudinal grooves in nail. (5) Confetti skin lesions: multiple 1-3 mm hypopigmented macules scattered in 'confetti' pattern, especially on extremities. Less specific (can be seen in 1% of normal population) but increased frequency in TSC. Other cutaneous findings: facial fibrous plaques (forehead plaques, often present at birth), molluscum-like fibromas, café-au-lait spots, dental enamel pitting (multiple), oral fibromas (gingival).

Systemic manifestations: (1) Neurologic: cortical and subcortical tubers (focal cortical dysplasia, hamartomas), subependymal nodules, subependymal giant cell astrocytomas (SEGA, present in 5-15%, can cause hydrocephalus from obstruction at foramen of Monro). Clinical: epilepsy in 80-90% (infantile spasms, focal seizures), cognitive disability in 50%, autism spectrum disorder in 25-50%, behavioral problems. (2) Renal: angiomyolipomas (benign tumors of fat, smooth muscle, blood vessels, present in 70-80%, risk of spontaneous hemorrhage if larger than 3-4 cm), renal cysts, rare renal cell carcinoma. (3) Cardiac: rhabdomyomas in 50% of TSC infants, often regress spontaneously after age 2-4 years, may cause arrhythmias or outflow obstruction. (4) Pulmonary: lymphangioleiomyomatosis (LAM) in approximately 30% of women with TSC, causes progressive cystic lung disease with dyspnea, pneumothorax, chylothorax. (5) Ophthalmologic: retinal hamartomas (50%), retinal achromic patches. (6) Endocrine: rare carcinoid, paraganglioma, neuroendocrine tumors. Diagnosis: revised TSC diagnostic criteria 2012 (Northrup) requires either: definite TSC = 2 major features OR 1 major + 2 minor features, possible TSC = 1 major OR 2+ minor features. Genetic testing for TSC1 and TSC2 mutations available, identifies pathogenic mutation in 75-90% of clinically diagnosed cases. Treatment of cutaneous manifestations: facial angiofibromas — topical sirolimus 0.1-1% cream/ointment (off-label, FDA-approved formulation in 2022 with topical sirolimus) applied once daily, effective in reducing size and erythema with 8-12 weeks of therapy. Alternatives: pulsed dye laser (PDL) for vascular component, electrodessication, cryotherapy, dermabrasion, ablative CO2 laser, surgical excision for selected lesions. Hypomelanotic macules: cosmetic camouflage. Shagreen patches and ungual fibromas: surgical removal if symptomatic. Systemic mTOR inhibitors (sirolimus, everolimus) are FDA-approved for SEGA, renal angiomyolipoma (greater than 3 cm), refractory epilepsy in TSC, and LAM. They reduce tumor size and prevent progression. Multidisciplinary care with neurology (epilepsy management), nephrology, pulmonology (LAM), cardiology, dermatology, ophthalmology, genetics, and developmental specialists. TSC clinical surveillance recommendations: annual skin exam, neuroimaging every 1-3 years for SEGA monitoring (every year in childhood, every 2-3 years in adults), abdominal MRI/ultrasound every 1-3 years for renal angiomyolipoma, pulmonary function and chest CT for LAM in women, ECG, echocardiogram for rhabdomyoma, and ophthalmologic exam annually.